Form 4: Pfizer CEO Albert Bourla Exercises Stock Appreciation Rights, Adjusts Holdings

Pfizer's Chairman and CEO, Albert Bourla, executed stock appreciation rights, resulting in adjustments to his holdings of Pfizer common stock.

Summary

• On February 22, 2025, Albert Bourla, Chairman and CEO of Pfizer Inc., exercised stock appreciation rights, resulting in the acquisition of 238,399 shares of common stock at a price of $30.17.
• Following the transaction, Bourla directly owns 570,436 shares.
• Shares were withheld to cover tax obligations (8,835 shares at $26.3) and the exercise price (212,680 shares at $26.08) related to the stock appreciation rights.
• After these transactions, Bourla directly owns 348,921 shares and indirectly owns 5,357 shares through a Rule 16b-3 plan.

Sentiment

Score: 5

Explanation: This is a routine disclosure of executive stock transactions. It doesn't inherently indicate positive or negative sentiment, but rather reflects standard compensation practices.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are closely watched by investors as they can provide insights into management's perspective on the company's performance and future prospects.

Comparison to Industry Standards

• Executive compensation packages, including stock appreciation rights, are standard practice among large pharmaceutical companies like Pfizer, Johnson & Johnson, and Merck.
• The structure and terms of these packages are typically benchmarked against industry peers to attract and retain top talent.
• The reporting of these transactions via Form 4 filings is a regulatory requirement ensuring transparency for investors.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it involves the exercise of previously granted stock appreciation rights.
• The withholding of shares for tax and exercise price obligations reduces the number of newly issued shares.

Key Dates